期刊文献+

不同临床指标在不同病因HCC患者中的变化差异及预后意义 被引量:2

The variation and prognostic significance of different clinical indicators in different etiological hepatocellular carcinoma patients
下载PDF
导出
摘要 目的分析乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)单一感染及合并感染肝癌(HCC)与非病毒感染HCC(UV-HCC)患者不同临床指标的变化差异,并探讨其在HCC中的预后价值。方法回顾性分析延边大学附属医院2000—2016年HCC患者2 634例,按病因学分为HBV-HCC组、HCV-HCC组、HBV/HCV-HCC组、UV-HCC组,比较各组在不同临床指标上的变化差异,并与终末期肝病模型(MELD)评分进行相关性分析,探索其预后价值。结果四组血小板(PLT)、血红蛋白(Hb)、凝血酶原时间(PT)、国际标准化比值(INR)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、清蛋白(ALB)、谷氨酰转肽酶(GGT)、总胆红素(TBIL)、空腹血糖(GLU)指标均有明显差异(P<0.01);而四组尿素氮(BUN)、血清肌酐(CREA)水平比较,差异均无统计学意义(P>0.05)。Spearman等级相关分析结果显示,HCC患者PT、INR、AST、ALT、GGT、TBIL、CREA指标与MELD评分均存在显著相关性(P<0.001)。结论 UV-HCC与HBV-HCC、HCV-HCC和HBV/HCV-HCC在PLT、PT、INR、AST、ALT、ALB、GGT、TBIL水平上均有显著差异,而HCV-HCC与HBV/HCV-HCC在各指标水平上均无显著差异;HBV-HCC中PLT、Hgb、ALB、GGT水平均高于HCV-HCC。PT、INR、AST、ALT、GGT、TBIL、CREA与HCC的预后显著相关,且不同指标在不同病因HCC患者中的预后价值不同,GGT在HBV-HCC患者中的预后价值显著优于其他指标。 Objective To analysis the variation of clinical index expression between hepatocellular carcinoma (HCC) patients caused by hepatitis B virus (HBV), hepatitis C virus(HCV) single or combined infection and HCC patients caused by non-viral infections(UV-HCC). Methods Retrospective analysis of Affiliated Hospital of Yanbian University 2 634 cases of HCC patients fi'om 2000 to 2016, according to the etiology patients were divided into HBV-HCC group, HCV-HCC group, HBV/ HCV-HCC group and UV-HCC group, compared the variation of different clinical indicators between groups and evaluate the prognostic value by correlation analysis with MELD score. Results Platelet(PLT) ,hemoglobin (Hb),prothrombin time (PT), international standardization ratio (INR), alanine aminotransferase(ALT), aspartate aminotransferase (AST), albumin (ALB), glutamyl transpeptidase (GGT), total bilirubin (TBIL) were all different in the four groups, the differences were statistically significant(P〈0.01).There was no difference between BUN and CREA in the four groups, there were no statistical significance (P〉0.05).The results of Spearman rank con'elation showed that PT, INR, AST, ALT, GGT, TBIL, CREA were significantly- cor- related with MELD score in HCC patients (P〈0.001). Conclusion There are significant differences in the levels of PLT, PT, INR, AST, ALT, ALB, GGT and TBIL in HCC patients with virus infection and non-viral infections. All indicators have no dif- ferences in HCC patients caused by HBV, HCV single or combined infection; in HBV-HCC patients PLT, Hbg, ALB and GGT was higher than HCV-HCC patients. PT, INR, AST, ALT, GGT, TBIL, CREA are significantly correlated with the prognosis of liver cancer, and the prognostic value of different indicators in HCC patients caused by different etiology are different. The prog- nostic value of GGT is significantly- better than other indicators in HBV-HCC patients.
作者 曹艳平 隋洪婷 潘猛 曲宝聚 朴红心 CAO Yanping;SUI Hongting;PAN Meng;QU Baoju;PIA O Hongxin(Affiliated Hospital of Yanbian University,Yan-ji,Jilin 133000,China)
出处 《现代医药卫生》 2018年第21期3271-3274,共4页 Journal of Modern Medicine & Health
基金 国家自然基金资助项目(81360075)
关键词 肝癌 肝炎病毒属 预后 临床指标 Liver neoplasms Hepacivirus Prognosis Clinical indicators
  • 相关文献

参考文献4

二级参考文献37

  • 1Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002[J]. CA Cancer J Clin, 2005, 55(1) : 74-108.
  • 2邬少明,孙宗棠,吴玉英,等.北京及启东居民尿黄曲霉毒素M1(AFMl)排出水平的研究[J].中华肿瘤杂志,1984,6(3):163-167.
  • 3Flor H, Pujol, PhD MD, et al. Genotypic variability of hepatitis viruses associated with chronic infaction and the development of hepatocellular carcinoma[J]. Clin Gastroenterol, 2005, 39 (7) : 611-618.
  • 4Geoffrey Dushei KO. The global burden of hepatitis C, and the hope for prophylactic HCV Vaccines [EB/OL ]. http: JJ wwwl. easl. ch/easl2006/pcourse/DusheiKO.
  • 5Amin J, Gidding HF, Gilbert G, et al. Hepatitis C prevalence - a nationwide serosurvey [J] . Communicable Diseases Intelligence, 2004,28(4) :517 -521.
  • 6Gregory L, Armstrong E, Annenmarie W. The prevalence of hepa- titis C virus(HCV) infection in the United States, 1999 - 2002 [ J] . Annals of Internal Medicine, 2006,144 ( 10 ) : 705 - 715.
  • 7de Baere T, Tselikas L, Pearson E, et al. Interventional oncotogy for liver and lung metastases from colorectal cancer:The current state of the art [ J ]. Diagnostic and Interventional Imaging, 2015,96 : 647- 654.
  • 8Sanfim M, E1-Haddad GE, Molenaar IQ, et al. 18F Fluorodeoxyglu- cose PET for Interventional Oncology in Liver Malignancy[ J]. PET Clinics, 2014,9:469-495.
  • 9Hosein PJ, Echenique A, Loaiza-Bonilla A, et al. Percutaneous hTe- versible Electroporation for the Treatment of Colorectal Cancer Liver Metastases with a Proposal for a New Response Evaluation System [J]. Journal of Vascular and Interventional Radiology, 2014,25: 1233-1239.
  • 10Adam SZ, Miller FH. Imaging of the Liver Following Interventional Therapy for Hepatic Neoplasms [ J ]. Radiologic Clinics of North A- merica,2015,53 : 1061-1076.

共引文献28

同被引文献20

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部